Literature DB >> 6809223

Potential anticonvulsive properties of endogenous prostaglandins formed in mouse brain.

U Förstermann, R Heldt, F Knappen, G Hertting.   

Abstract

The levels of 5 different prostanoids (PGD2, PGF2 alpha, PGE2, TXB2 and 6-keto-PGF1 alpha) formed in whole mouse brain in vivo were measured by specific radioimmunoassays. Basal concentrations were found to be very low (few ng/g wet weight). A marKed increase occurred during convulsions induced by either pentylenetetrazole or by electroconvulsive shock. Under both conditions the major cyclooxygenase product detected was PGD2, followed by PGF2 alpha and lower concentrations of the other prostanoids. The non-steroidal anti-inflammatory drugs flurbiprofen, indomethacin, and diclofenac dose-dependently inhibited the pentylenetetrazole-induced formation of prostaglandins. Concomitantly these 3 compounds dose-dependently increased the acute toxicity of pentylenetetrazole (decrease in LD50). Conversely, if levels of cerebral prostaglandins were enhanced by a preceding electroshock, the toxicity of pentylenetetrazole was significantly reduced (increase in LD50), and the time of onset of clonic seizures was markedly prolonged. Both the effect on the latency time and the LD50 could be reversed if the cerebral prostaglandin synthesis was prevented by indomethacin, or if the time interval between the electroshock and pentylenetetrazole administration was extended, so that the electroshock-stimulated prostaglandin concentrations had declined to basal levels again. These findings indicate that endogenous prostanoids formed in mouse brain during convulsions might possess anticonvulsive properties.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6809223     DOI: 10.1016/0006-8993(82)90225-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Cyclooxygenase-2 expression and effect of celecoxib in flurothyl-induced neonatal seizure.

Authors:  Doo Kwun Kim; Tae Jung Jang
Journal:  Int J Exp Pathol       Date:  2006-02       Impact factor: 1.925

2.  Animal Models of Posttraumatic Seizures and Epilepsy.

Authors:  Alexander V Glushakov; Olena Y Glushakova; Sylvain Doré; Paul R Carney; Ronald L Hayes
Journal:  Methods Mol Biol       Date:  2016

3.  Neuromodulatory role of endogenous interleukin-1β in acute seizures: possible contribution of cyclooxygenase-2.

Authors:  Robert J Claycomb; Sandra J Hewett; James A Hewett
Journal:  Neurobiol Dis       Date:  2011-08-10       Impact factor: 5.996

4.  Effects of intracerebroventricular administration of prostaglandin D2 on behaviour, blood pressure and body temperature as compared to prostaglandins E2 and F2 alpha.

Authors:  U Förstermann; R Heldt; G Hertting
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  Protective effect of prostaglandins D2, E1 and I2 against cerebral hypoxia/anoxia in mice.

Authors:  Y Masuda; Y Ochi; Y Ochi; T Karasawa; N Hatano; T Kadokawa; M Shimizu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

6.  Maintenance of the Innate Seizure Threshold by Cyclooxygenase-2 is Not Influenced by the Translational Silencer, T-cell Intracellular Antigen-1.

Authors:  Yifan Gong; James A Hewett
Journal:  Neuroscience       Date:  2018-01-11       Impact factor: 3.590

7.  Regional distribution of prostanoids in rat brain: effect of insulin and 2-deoxyglucose.

Authors:  E Shohami; M Globus; J Weidenfeld
Journal:  Exp Brain Res       Date:  1985       Impact factor: 1.972

8.  Cyclooxygenase-2 is a neuronal target gene of NF-kappaB.

Authors:  Barbara Kaltschmidt; Ralf A Linker; Jinbo Deng; Christian Kaltschmidt
Journal:  BMC Mol Biol       Date:  2002-12-04       Impact factor: 2.946

9.  Expression of class II histone deacetylases in two mouse models of temporal lobe epilepsy.

Authors:  Rohan Jagirdar; Meinrad Drexel; Anneliese Bukovac; Ramon O Tasan; Günther Sperk
Journal:  J Neurochem       Date:  2015-12-28       Impact factor: 5.372

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.